Scientific Poster Session III - Original Research

Abstract

Research Question or Hypothesis:

Study Design:

Methods:

Inpatients = 65 years, administered an antipsychotic between August 2021 and August 2023 were screened. Exclusion criteria included: home use of antipsychotic or benzodiazepine, mood disorder except major depressive disorder, admission to the intensive care unit for = 48 hours or intubation, benzodiazepine administration, or developmental delay. Low dose was defined as patients receiving haloperidol (0.5 – 1 mg/dose), olanzapine (2.5 – 5 mg/dose), quetiapine (12.5 – 25 mg/dose), risperidone (0.25 – 1 mg/dose), or ziprasidone (10 – 20 mg/dose). High dose was any dose above low. The primary outcome was re-dosing within 6 hours of initial dose. Secondary outcomes included length of stay (LOS), continuation of antipsychotics on discharge, and adverse events (e.g. falls). Between group comparisons and outcome data were analyzed using Mann-Whitney U test and Chi-squared test or Fisher’s exact test as appropriate (GraphPad Prism version 10.0.0). Alpha was <0.05.

Results: Of the 305 patients included, 25 (14%) low dose patients compared to 18 (14%) high dose required re-dosing of an antipsychotic in = 6 hours (p=0.9504). The median (IQR) LOS was [5 days (3–10) vs 6 (3–10); p=0.59)], discharge antipsychotics prescribed [49 (28%) vs 33 (26%), p=0.66), and adverse events [43 (24%) vs. 38 (29%); p=0.33] were not significantly different between low and high groups respectively.

Conclusion: